FDA should follow EMA's lead on drug rejection disclosures, researchers say
The FDA's major shift in September 2025 to begin publishing drug rejection letters is still an evolving process. But moving forward, the US agency should improve its releases by learning from the European Medicines Agency's ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.